Institute of Biophysics of Chinese Academy of Sciences

TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus (SARS-CoV-2) outbreak, the Company was granted an Emergency Use Authorization ("EUA") for its two-component recombinant COVID-19 vaccine ReCOV by Order No. A106 of the Minister of Public Health of Mongolia and a resolution of the Mongolian Committee for Medicinal Products for Human Use. This product is designed and developed by the Group jointly with Professor Wang Xiangxi' s group at the Institute of Biophysics, Chinese Academy of Science, and is the first novel adjuvant recombinant subunit COVID-19 vaccine developed in China and approved overseas. Novel adjuvant has become a key factor in the successful research and development of innovative vaccines in China, and has become one of the key research projects in the development plan of China's pharmaceutical industry during the 14th Five-Year Plan. ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms, including its novel adjuvant, protein engineering and immunological evaluation platforms, and the adjuvant used therein is its self-developed novel adjuvant BFA03. The Company has successively conducted multiple late-stage clinical studies for ReCOV in China, the Philippines, the United Arab Emirates, Nepal and Russia. Studies have shown that ReCOV has demonstrated favorable safety profile, with mild adverse reactions and no vaccine-related serious adverse events. In particular, in a comparative clinical study with a positive control of the Pfizer's mRNA vaccine, a sequential booster of ReCOV among subjects who have completed vaccination of inactivated vaccines induced durable and widespread cross-neutralizing antibodies against various Omicron variants, including BF.7, BA.5, BA.2.75, and BA.2, with all subgroups achieving superior levels of neutralizing antibodies as compared to the Pfizer's mRNA vaccine (with statistically significant differences). The granting of the EUA to ReCOV in Mongolia will benefit the Group's expansion into overseas market, enhancement of the Group's overseas brand awareness and promotion of the Group's internationalization strategy, and will play a positive role in promoting the registration in other countries and regions. About Recbio Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 02179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). Staying true to the mission of "Protect human health with best-in-class vaccines", the Company has established high-value pipelines consisting of several blockbuster vaccines with proprietary rights to satisfy the huge unmet demands in the markets of high-burden diseases. Through years of devotion to the vaccine industry, Recbio has developed three advanced innovative technology platforms, namely novel adjuvant, protein engineering and immunological evaluation platforms, and become one of the few companies in the world capable of developing novel adjuvant systems. We develop promising vaccine candidates constantly, taking advantage of the synergy between the novel adjuvant platform, optimized antigen designs, and immunological evaluation technologies. Recbio never ceases to optimize its technology platforms, and strives to achieve breakthroughs in mRNA vaccines using a joint venture model. With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial, shows great promise of becoming the first marketed domestic 9-valent HPV vaccine. Apart from that, ReCOV, a recombinant COVID-19 vaccine with its commercialization in the offing, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market. Honed and refined for ten years, Recbio is going to reap the rewards as several products are approaching commercialization. For more information, please visit . Forward-looking statements This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein. Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited () or of the Company () for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail. Jiangsu Recbio Technology Co., Ltd. Investor Inquiry: Email: [email protected] Tel: +86-0523-86818860 Media Inquiry: Email: [email protected] Tel: +86-0523-86818860

LONDON, June 30, 2022 /PRNewswire/ -- Clinical Laboratory Test Market Size, Share, Companies & Trends Analysis Report By Type (Complete Blood Count, Comprehensive Metabolic Panel, HGB/HCT, BUN Creatinine Tests, Basic Metabolic Panel, Electrolytes Testing, Lipid Panel, Liver Panel, HbA1c Tests, Renal Panel), By Test (Specialty, Routine), By Department (Parasitology, Urinalysis, Virology, Immunology/Serology, Hematology, Histopathology, Toxicology), By Service Provider (Clinic-Based Laboratories, Hospital-Based Laboratories, Stand-Alone Laboratories), Based On Region And Segment Forecasts, 2022 – 2028 Report Published by Brandessence Market Research. Increasing prevalence of chronic diseases, rising cases of cardiovascular disease, and growing technological advancements are some of the major factors driving the growth of the Global Clinical Laboratory Test Market. Key Points: Global Clinical Laboratory Test Market size was valued at USD 193.3 Billion in 2021. Clinical Laboratory Test Market is expected to reach USD 320.7 Billion by 2028. Market Size is Moving at CAGR of 7.5% over the forecast period. Get Sample of [email protected] Clinical Laboratory Test Market: Market Scope The global clinical laboratory test market has been expected to see a continuous growth in the coming years while there has been a continuous growth in the last few years. There is an increased prevalence of the chronic diseases and there is rise in the awareness among the people who are now conscious for their health and that has fueled the market's growth in the worldwide market. There is a demand in the clinical laboratory tests has been driven by the growth in the investments in the diagnosis of target diseases like the cardiovascular disorders, diabetes and tuberculosis. The clinical laboratory tests are helping people diagnose the diabetes mellitus. As per different reports it has been reported that the growth of diabetes is going to grow in the coming two decades. Clinical Laboratory Test Market: Competitive Analysis The global clinical laboratory test market's key players are the companies like ARUP Laboratories, Abbott, Bioscientia Institut für Medizinische Diagnostik GmbH, OPKO Health, Inc., NeoGenomics Laboratories, Inc., Charles River, Healthscope Ltd., Genoptix, Inc., Fresenius Medical Care, Labco, Laboratory Corporation of America Holdings (LabCorp), QIAGEN, Tulip Diagnostics (P) Ltd., Quest Diagnostics, Siemens Healthcare Private Limited, Merck KgaA Biosino Bio-technology, and Sonic Healthcare. The clinical laboratory test companies 2021 are focusing in a detailed manner on getting together to share technology and make a market which can help scale into the emerging markets. Biosino Biotechnology and Science Inc. Abbott Siemens Healthcare Private Limited Laboratory Corporation of America Holdings (LabCorp) OPKO Health, Inc. Fresenius Medical Care NeoGenomics Laboratories, Inc. Quest Diagnostics Sonic Healthcare Merck KgaA Others Clinical Laboratory Test Market: Segmentation Analysis On the basis of end use, the primary clinics segment has been growing in the last few years with the rapid tests increasing in demand for the rapid results as there is growth in the awareness about laboratories. In terms of type, the Basic metabolic tests have been growing in the market as there is also an increase in the clinical laboratory test market size which is due to the growth in self-awareness in urban centres. Global Clinical Laboratory Test Market Segmentation: By Type Complete Blood Count Comprehensive Metabolic Panel HGB/HCT BUN Creatinine Tests Basic Metabolic Panel Electrolytes Testing Lipid Panel Liver Panel HbA1c Tests Renal Panel By Test Specialty Routine By Department Parasitology Urinalysis Virology Immunology/Serology Hematology Histopathology Toxicology Others By Service Provider Clinic-based Laboratories Hospital-based Laboratories Stand-alone Laboratories Buy now of this repot: Clinical Laboratory Test Market: Key Drivers There is an increase in the overall geriatric population all over the world which has been expected to drive the market overall for the clinical laboratory tests. As per the different stats published by different agencies it has been reported that the geriatric population levels are growing continuously and it is going to increase the demand for different clinical tests as they are vulnerable to different tests. Furthermore, the global clinical laboratory test market growth is due to the growth in the rate of insufficient physical exercise, the consumption of unhealthy foods as well as the rise subsequently in the cases of obesity will be increasing the prevalence of different chronic diseases. The rise in the awareness of the necessity of a regular body profiling among the healthcare professionals as well as the global patients will be increasing the demand for the clinical laboratory tests. The clinical laboratory tests have over the years been the backbone of diagnosis of diseases and the monitoring of therapeutic responses during the prognosis. This isn't only to meet the individual patient needs, but it can also help in making important and timely interventions in the public programs, healthcare programs all over the world. The standardizations of the laboratory services have been helping the fuel strides in the global programs for health. The standardizations of the laboratory services has been helping the global health programs in gaining strides. The standardizations for the laboratory services have been helping in the expansion of the clinical laboratory test market. The approaches are patient-centred in terms of management of the diseases particularly in the chronic conditions and also the viral diseases. This will help take strides towards newer avenues. The global clinical laboratory test market statistics suggest that all over the world, the healthcare systems on the achievement of the primary goals of the medical laboratory testing has been increasingly working on the clinical efficacy and effectiveness. The ultimate objective here is to offer the patients an access to the timely and quality care, the propelling strides in clinical laboratory test market. In the developed nations most of the decisions which are taken on the clinical levels have been based on the tests which are conducted here. Get Methodology @ Clinical Laboratory Test Market: Key Trends The global clinical laboratory test market trends suggest that in the recent past, the need for the diagnostic testing which is of the highest quality is a very important part for the quality care of the patients. This is driving the major aspect of propelling the strides in the clinical laboratory test market. The rise in the incidences of the chronic diseases as well as the growth in the morbidity of the non-communicable diseases has intensified the need for the early diagnosis. In both the systems of public and private health have grown very cautious about the increasing the access to the diagnostic specific and confirmatory tests. It is due to this that there is funding which is raised to strengthen their clinical lab infrastructures. In the recent past, the need for clinical lab tests for the screening and surveillance of the diseases in the public health emergencies has created a new horizon for the stakeholders in the clinical laboratory test market. In the developing economies, the hospitals are stressed on the convenience and ease of the consumers and therefore ensuring that there is an infrastructure which exists in a robust manner in a closer proximity. There is a focus that has been imparting a marked impetus for the expansion of the clinical laboratory test market. Clinical Laboratory Test Market: Regional Analysis In the clinical laboratory test market 2022, the region of North America has been growing in the last few years and that is because of the penetration of the advanced diagnostic techniques as well as the increase in test volumes which support the regional market dominance. Further a factor that is working for the market in this region is the fact that the geriatric population of the region is growing at a rapid rate. This is where the market will see a continuous growth. The region of Asia Pacific is also going grow in the coming years as well with the lifestyle becoming sedentary. On Special Requirement Clinical Laboratory Test Market Report is also available for below region: North America U.S, Canada Europe Germany, France,U.K., Italy, Spain, Sweden, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe Asia-Pacific South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC Latin America Mexico, Colombia, Brazil, Argentina, Peru, Rest of Latin America Middle East and Africa Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA Get Full Access of all Report: Related Reports: Pyrogen Testing Market By Product (Instruments, Consumables, Services), By Test (LAL (Limulus Amebocyte Lysate) Tests (Turbidimetric Test, Chromogenic Test, Gel Clot Test), In Vitro Tests, Rabbit Tests), By Application (Pharmaceutical & Biologics, Medical Devices, Diagnostics), Industry Analysis, Trends, And Forecast, 2022-2028 EPharmacy Market By Drug Type (Prescription Drugs, Over-The-Counter (OTC) Drugs), By Product Type (Skin Care, Dental, Cold And Flu, Vitamins, Weight Loss), Industry Analysis, Trends, And Forecast, 2021-2027 Neurological Disorder Diagnostics Market is expected to reach USD 18273.57 Million by 2025 Insulin Pump Market is estimated to reach about USD 8740.87 Million by the end of 2024 Endoscope Market By Product (Rigid Endoscope, Flexible Endoscope, Capsule Endoscope, Robot-Assisted Endoscope), By Application (Bronchoscopy, Arthroscopy, Laparoscopy, Urology Endoscopy, Neuroendoscopy, Gastrointestinal Endoscopy, Obstetrics/Gynecology Endoscopy, ENT Endoscopy), Industry Analysis, Trends, And Forecast 2022-2028 Healthcare Analytics Market is expected to reach USD 108.01 Billion by 2025 | CAGR 26.48% Smart Thermostat Market is expected to reach USD 7181.32 Million by 2025 with CAGR of 23.40% Liver Fibrosis Drug Market is expected to reach USD 22.0 Billion By 2025 Lithotripsy Devices market is expected to reach USD 1896.93 million by 2025 Adhesive Dispensing Equipment Market is expected to reach USD 12760.8 Million by 2028 i-Factor: Live Market intelligence platform I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, chang ing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trail here @ Brandessence Market Research & Consulting Pvt ltd. Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London. Blog: Radiopharmaceuticals Market Follow Us: Linkedin Mr. Vishal Sawant Email: [email protected] Email: [email protected] Corporate Sales: +44-2038074155 Asia Office : +917447409162 Logo: SOURCE Brandessence Market Research and Consulting Private Limited

Over the last two decades, microscopy has seen unprecedented advances in speed and resolution. However, cellular structures are essentially three-dimensional, and conventional super-resolution techniques often lack the necessary resolution in all three directions to capture details at a nanometer scale. A research team has now investigated a super-resolution imaging technique that involves combining the advantages of two different methods to achieve the same resolution in all three dimensions; this is 'isotropic' resolution. Over the last two decades, microscopy has seen unprecedented advances in speed and resolution. However, cellular structures are essentially three-dimensional, and conventional super-resolution techniques often lack the necessary resolution in all three directions to capture details at a nanometer scale. A research team led by Göttingen University, including the University of Würzburg and the Center for Cancer Research in the US, investigated a super-resolution imaging technique that involves combining the advantages of two different methods to achieve the same resolution in all three dimensions; this is "isotropic" resolution. The results were published in Science Advances. Despite tremendous improvements in microscopy, there still exists a remarkable gap between resolution in all three dimensions. One of the methods that can close this gap and achieves a resolution in the nanometer range is metal-induced energy transfer (MIET) imaging. The exceptional depth resolution of MIET imaging was combined with the extraordinary lateral resolution of single-molecule localization microscopy, in particular with a method called direct stochastic optical reconstruction microscopy (dSTORM). The novel technique based on this combination allows researchers to achieve isotropic three-dimensional super-resolution imaging of sub-cellular structures. In addition, the researchers implement dual-color MIET-dSTORM enabling them to image two different cellular structures in three dimensions, for example microtubules and clathrin coated pits -- tiny structures within cells -- that exist together in the same area. "By combining the established concepts, we developed a new technique for super-resolution microscopy. Its main advantage is it enables extremely high resolution in three dimensions, despite using a relatively simple setup," says Dr Jan Christoph Thiele, first author of the publication, Göttingen University. "This will be a powerful tool with numerous applications to resolve protein complexes and small organelles with sub-nanometer accuracy. Everyone who has access to confocal microscope technology with a fast laser scanner and fluorescence lifetime measurements capabilities should try this technique," says Dr Oleksii Nevskyi, one of the corresponding authors. "The beauty of the technique is its simplicity. This means that researchers around the world will be able to implement the technology into their microscopes quickly," adds Professor Jörg Enderlein who led the research team at the Biophysics Institute, Göttingen University. This method shows promise to become a powerful tool for multiplexed 3D super-resolution microscopy with extraordinary high resolution and a variety of applications in structural biology.